[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100370681":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":28,"responsibleParty":105,"collaborators":10,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":109,"sex":114,"minAge":115,"maxAge":10,"enrollmentInfo":116,"targetDuration":119,"studyType":120,"phases":10,"briefSummary":121,"conditions":122,"keywords":126,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"University Hospital, Lille","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"cirrhosis",null,"Patients with alcoholic liver disease without alcoholic hepatitis",{"label":13,"type":10,"description":14,"interventionNames":10},"severe alcoholic hepatitis","Patients with severe alcoholic hepatitis ( Maddrey score ≥32)",{"label":16,"type":10,"description":17,"interventionNames":10},"non-severe alcoholic hepatitis","Patients with non-severe alcoholic hepatitis (Maddrey score \\\u003C32)",[19],{"name":20,"affiliation":5,"role":21},"Alexandre Louvet, MD,PhD","PRINCIPAL_INVESTIGATOR",[23],{"name":20,"role":24,"phone":25,"phoneExt":26,"email":27},"CONTACT","03 20 44 55 97","+33","alexandre.louvet@chru-lille.fr",[29,41,49,57,65,73,81,89,97],{"facility":30,"status":31,"city":32,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":10},"Chr Angers","RECRUITING","Angers","France","FR",{"type":36,"coordinates":37},"Point",[38,39],-0.55202,47.47156,{"lat":39,"lon":38},{"facility":42,"status":31,"city":43,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":44,"geoPoint":48,"contacts":10},"Chru Besancon","Besançon",{"type":36,"coordinates":45},[46,47],6.01815,47.24878,{"lat":47,"lon":46},{"facility":50,"status":31,"city":51,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"Hôpital Jean Verdier, AH-HP","Bondy",{"type":36,"coordinates":53},[54,55],2.48931,48.9018,{"lat":55,"lon":54},{"facility":58,"status":31,"city":59,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":60,"geoPoint":64,"contacts":10},"Centre Hospitalier Universitaire","Caen",{"type":36,"coordinates":61},[62,63],-0.35912,49.18585,{"lat":63,"lon":62},{"facility":66,"status":31,"city":67,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":68,"geoPoint":72,"contacts":10},"Hopital Nord - Chu38 - La Tronche","La Tronche",{"type":36,"coordinates":69},[70,71],5.74629,45.20507,{"lat":71,"lon":70},{"facility":74,"status":31,"city":75,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":76,"geoPoint":80,"contacts":10},"Hôpital Claude Huriez, CHU","Lille",{"type":36,"coordinates":77},[78,79],3.05512,50.63391,{"lat":79,"lon":78},{"facility":82,"status":31,"city":83,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":84,"geoPoint":88,"contacts":10},"Association Hopital Saint Joseph - Marseille","Marseille",{"type":36,"coordinates":85},[86,87],5.38107,43.29695,{"lat":87,"lon":86},{"facility":90,"status":31,"city":91,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":92,"geoPoint":96,"contacts":10},"Chu Montpellier","Montpellier",{"type":36,"coordinates":93},[94,95],3.87635,43.61093,{"lat":95,"lon":94},{"facility":98,"status":31,"city":99,"state":10,"zip":10,"country":33,"countryCode":34,"cosmosGeoPoint":100,"geoPoint":104,"contacts":10},"Hu Est Parisien Site St Antoine Aphp - Paris 12","Paris",{"type":36,"coordinates":101},[102,103],2.3488,48.85341,{"lat":103,"lon":102},{"type":106,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100370681","study-of-genetic-determinants-in-alcoholic-hepatitis-and-establishment-of-a-multicenter-prospective-cohort-of-patients-with-alcoholic-liver-disease-100370681",false,"NCT04106518","Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease","COMADHAA","Inclusion Criteria:\n\nFor SAH group:\n\n* Alcohol consumption :\n\n  * On average\\> 40 g \u002F day for women and 50 g \u002F day for men\n  * Duration:\\> 5 years\n* Recent jaundice episode (less than 3 months)\n* Bilirubin\\> 50 mg \u002F l (85μmol \u002F l)\n\nFor NSAH group:\n\n\\- Alcohol consumption :\n\n* On average\\> 40 g \u002F day for women and 50 g \u002F day for men\n* Duration:\\> 5 years\n\nFor cirrhosis (control) group:\n\n* Alcohol consumption :\n\n  * On average\\> 40 g \u002F day for women and 50 g \u002F day for men\n  * Duration:\\> 5 years\n* Unambiguous presence of cirrhosis criteria, including:\n\n  * clinical signs (ascites, stellar angiomas ...) and \u002F or\n  * radiological signs (scanner or MRI: signs of hepatic dysmorphism and \u002F or portal hypertension) and \u002F or\n  * biological signs (increased INR, thrombocytopenia) and \u002F or\n  * endoscopic signs (oesophageal \u002F gastric varices)\n\nExclusion Criteria:\n\nFor NAH and NSAH groups:\n\n* Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)\n* Presence of hepatocellular carcinoma\n* HIV infection\n\nFor cirrhosis (control) group:\n\n* History established \u002F suggestive of HAA (Clinical, biological and \u002F or histological criteria) in particular absence of jaundice episode\n* Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)\n* Presence of hepatocellular carcinoma\n* HIV infection","ALL","18 Years",{"count":117,"type":118},447,"ESTIMATED","5 Years","OBSERVATIONAL","Alcoholic hepatitis carries a risk of high mortality at short term, especially in its severe form. Its diagnosis is confirmed by liver biopsy. The prevalence of alcoholic hepatitis, severe or not severe, is poorly known and prospective data are needed. The present observational study aims to define the prevalence of alcoholic hepatitis among patients admitted for jaundice and determine their outcome according to the severity. Survival and markers of liver dysfunction will be assessed. A biobank including genetic samples will be created to identify the disease profile in terms of inflammation and regeneration. The performance of non-invasive criteria for diagnosis will also be studied.",[123,124,125],"Alcoholic Liver Disease","Severe Alcoholic Hepatitis","Alcoholic Cirrhosis",[127,128,129,130,131,132],"Cohort","alcoholic hepatitis","alcoholic cirrhosis","pathophysiology","bio bank","pan-genomic study","2026-05-18",{"date":135,"type":136},"2026-05-19","ACTUAL",{"date":138,"type":136},"2019-10-23",{"date":140,"type":118},"2027-04",{"name":5,"class":6},9]